Rybelsus is the trade name of a drug based on the active substance semaglutide, which is produced by the pharmaceutical company Novo Nordisk AS, Denmark. According to the clinical and pharmacological group, semaglutide belongs to hypoglycemic drugs. To be more precise, the drug is a glucagon-like peptide-1 (GLP-1) receptor agonist.

Rybelsus is used in adult patients with poorly controlled type 2 diabetes mellitus as an adjunct to diet and exercise. The consequence of taking the medication is improved glycemic control. Rybelsus can be used both as monotherapy (in cases where the use of metformin is not possible due to intolerance or contraindications) and in combination with other hypoglycemic drugs.

Semaglutide is a GLP-1 analogue. It has almost 95% homology with human GLP-1. Semaglutide reduces body weight and adipose tissue mass by reducing energy intake, including a general reduction in appetite. In addition, semaglutide reduces the preference for eating foods high in fat, which has a beneficial effect on the body of a patient with type 2 diabetes due to weight loss and a decrease in the amount of sugar entering the body.

GLP-1 is a physiological hormone that has several effects on the regulation of glucose concentration and appetite, as well as on the cardiovascular system.

Semaglutide reduces blood glucose concentrations by stimulating insulin secretion and suppressing glucagon secretion when blood glucose concentrations are high. Also, the mechanism for reducing the concentration of glucose in the blood is associated with a slight delay in gastric emptying in the early phase of digestion. Moreover, during hypoglycemia, semaglutide reduces insulin secretion and does not interfere with glucagon secretion. In addition to its direct effect on glucose metabolism, semaglutide has a positive effect on plasma lipids, reduces systolic blood pressure and reduces inflammation. Rybelsus helps slow the development of atherosclerosis, prevents the progression of the formation of arterial plaques and reduces inflammation in them.

Rybelsus is available as a white to light yellow, oval, biconvex, oral tablet engraved with the strength on one side and the word Nova on the other. Patients are available in dosages such as 3, 7 and 14 mg. Typically, the starting dose of Rybelsus is 3 mg once daily for one month. Then the dosage is increased to 7 mg once a day. Often, after another 1-2 months, the dosage is adjusted to the maintenance dosage, which is 14 mg once a day. The drug is taken on an empty stomach at approximately the same time of day, swallowing the tablet whole and drinking it down with water.

The treatment period for Rybelsus is very long: doctors recommend taking this medicine for at least 26 weeks, often up to 80 weeks and more. Often, after the agreed period of treatment, patients again receive a similar prescription and take the medicine for literally years. In this regard, the issue of purchasing Rybelsus generics is especially relevant, because they help save up to 87% of the cost of the original medicine. If a patient is looking to control their blood sugar levels without spending unnecessarily large sums of money on a drug, the best choice is to buy Rybelsus online (Save $50 on Your Rybelsus Purchase with Our Exclusive Coupon 2024!) - or, more precisely, any of the many generic versions of this drug. They all contain the same active ingredient in the same dosages as the branded medicine. Only the trade names of the drugs, the size and color of the tablets, and sometimes their shape differ. However, all these points are insignificant, and the essence of the medicine remains unchanged, no matter which manufacturer produces its version of this medicine.